Supriya Lifescience Limited executed a long-term Supply and Sales Agreement (hereinafter "Agreement") on May 23, 2023, with a leading Company in Europe for the supply of Active Pharmaceutical Ingredient (API) for a period of 10 years. The business potential would be approximately INR 400 Million per year at its peak. The peak volumes are expected to happen in Fiscal Year 27.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
378.8 INR | -1.03% | -1.42% | +20.37% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.37% | 365M | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- SUPRIYA Stock
- News Supriya Lifescience Limited
- Supriya Lifescience Limited Executes A Long-Term Supply and Sales Agreement with A Leading Company in Europe for the Supply of Active Pharmaceutical Ingredient